Sabico S, et al. - In this randomized, double-blind, placebo-controlled trial, researchers described the beneficial impacts of probiotics on decreasing endotoxin levels and other cardiometabolic parameters in Arab patients with type 2 diabetes mellitus (T2DM). For this investigation, Saudi adults with naïve T2DM were randomly allocated to receive twice daily placebo or 2.5×10⁹cfu/gram of Ecologic®Barrier in a double-blind manner over a 6 month period, respectively. According to the findings obtained, multi-strain probiotic supplementation over 6 months as a monotherapy significantly reduced homeostasis model assessment for insulin resistance (HOMA-IR) in T2DM patients, with the probiotic treatment group highlighting decreased inflammation and improved cardiometabolic profile. Between the probiotic or placebo group at 3 and 6 months in other markers, no other clinically significant changes were noted. The study findings suggested that multi-strain probiotics were a promising adjuvant anti-diabetes therapy.